Israeli Treatment May Slow ALS Progression by 73%, Improve Survival Rates

Thus far, only two ALS drugs have been approved by the FDA, but these may only delay the progression of the disease by a few months.

By Shula Rosen

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, has no cure, yet a new Israeli treatment may slow the progression of the disease by 73% and dramatically improve survival rates.

That is welcome news regarding a disease that usually results in disability and death within two to five years of diagnosis.

Although the disease is rare, it can be a tragedy for patients and their families. Therefore, a drug that can improve mobility and extend the lifespans of people living with ALS will revolutionize the lives of thousands of people affected by it.

ALS is a neurodegenerative disease caused by the death of motor neurons and affects 450,000 people worldwide.

Thus far, only two ALS drugs have been approved by the FDA, but these may only delay the progression of the disease by a few months.

That is why Neurosense’s clinical trial is so impressive, especially if it can lead to FDA approval.

NeuroSense, founded in 2017 with headquarters in Herzliya, Israel, developed a treatment called PrimeC, which uses multiple pathways to treat ALS.

PrimeC is a fixed-dose drug containing ciprofloxacin and celecoxib, which targets microRNA dysregulation, iron accumulation, and neuroinflammation.

In previous clinical trials, PrimeC slowed the progression of the disease by 36% and improved survival rates by 43% compared to a placebo.

However, in the most recent clinical trial, PrimeC slowed the progression of ALS symptoms by 73% and increased survival rates by 63% compared to a placebo.

Alon Ben-Noon, NeuroSense’s CEO, commented: “We believe these results are unprecedented in a 12-month ALS placebo-controlled clinical study. We are eager to present them to the FDA and other regulatory agencies to determine the path forward and to share the outcomes with potential partners currently conducting due diligence.”

He added, “As a management team, we are both confident and enthusiastic about PrimeC’s potential in the market.”